Half Yearly Report Press Release Basingstoke, UK and Philadelphia, US - August 7, 2008 - In order to meet its obligations under the Disclosure Rules and Transparency Rules of the United Kingdom Financial Services Authority, Shire Limited ('Shire') (LSE: SHP,...
Noven Announces 2008 Second Quarter Financial Results - Noven Pharmaceuticals, Inc.(NASDAQ:NOVN) today announced financial results for the second quarter and first half of 2008.
Noven reported net income of $4.5 million or $0.18 diluted earnings per share for the quarter ended June 30,...
Noven to receive $25 million payment from Shire Payment of the milestone announced was triggered upon Shire's net sales of Daytrana exceeding $75 million in the 12-months preceding June 30, 2008.Under Noven's agreement with Shire, the $25 million milestone is due to be paid in...
Noven Pharma Q2 Profit Declines Yet Tops Estimates; Revenues Up 31% Noven Pharmaceuticals Inc.(NOVN: News, Chart, Quote ) Wednesday reported a decline in second quarter profit hurt by higher expenses and a voluntary product recall charge, even as revenue increased 31% from the prior-year quarter.
Noven Pharmaceuticals Inc to receive milestone from Shire Limited for Daytrana sales (M2 EQUITYBITES via COMTEX) -- NOVN | Quote | Chart | News | PowerRating -- Noven Pharmaceuticals Inc (NASDAQ: NOVN), a specialty pharmaceutical company, reported on 4 August that it will receive the third and final USD25m milestone payment...
Noven Pharmaceuticals Inc to receive milestone from Shire Limited for Daytrana sales Noven Pharmaceuticals Inc (NASDAQ: NOVN), a specialty pharmaceutical company, reported on 4 August that it will receive the third and final USD25m milestone payment from Shire Limited on net sales of Daytrana (methylphenidate...
Noven Announces Triggering of $25 Million Daytrana Sales Milestone MIAMI, Aug.4, 2008--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc.
(NASDAQ: NOVN) today announced that it has been advised by Shire Limited that Shires net sales of Daytrana (methylphenidate transdermal system) have triggered the...
Noven Announces Triggering of $25 Million Daytrana Sales Milestone MIAMI, Aug.4, 2008--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc.
(NASDAQ: NOVN) today announced that it has been advised by Shire Limited that Shires net sales of Daytrana (methylphenidate transdermal system) have triggered the...
Sales milestone met for Noven Daytrana was launched in June 2006.Payment of the milestone was triggered upon Shires net sales of Daytrana exceeding $75 million in the 12 months preceding June 30.
Under Novens agreement, the $25 million milestone is due...
Noven Achieves $25M Milestone under Collaboration with Shire for ADHD Therapy Noven Pharmaceuticals will receive $25 million from Shire under its agreement related to Daytrana. Shire achieved a sales level previously agreed to by both firms, thus triggering this milestone fee.
Under the terms of the...
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.Q2 2008 Financial Highlights - Product sales up...
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.Q2 2008 Financial Highlights - Product sales up...
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.Q2 2008 Financial...
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra ASINGSOE, England and PILADELPHIA, uly 31, 2008 /PRNewswire-FirstCall/ -- Shire Limited the global specialty biopharmaceutical company announces results for the three months to e 30, 2008.Q2 2008 Financial Highlights - Product sales up 40...
Noven Pharmaceuticals Inc: Corporate and Strategic Assessment Report - Company Strategy, SWOT Analysis and 5-y Published By: Datamonitor Page Count: 58 Order Code: R313-34249 Description Introduction Noven Pharmaceuticals (Noven) is a specialty pharmaceutical company engaged in the discovery, development, manufacture and commercialization of...
Shares of Miami-based drug firm tumble Shares of Miami-based Noven Pharmaceuticals fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.The stock lost 98 cents, or 9.1 percent, to $9.80 in afternoon...
Analyst Actions: Jefferies Cuts Rating on Noven Pharma - Plunges 10% (MidnightTrader via COMTEX News Network) -- Jefferies cut Noven Pharmaceuticals (NOVN) to 'underperform' vs 'hold' due to declining growth in sales of the Vivelle-Dot estrogen patch.Sales of the Daytrana attention deficit...
Noven Pharma falls after analyst cuts rating NEW YORK (AP) - Shares of Noven Pharmaceuticals Inc.fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.
Analyst David Windley lowered his rating to ...
Noven Pharma falls after analyst cuts rating NEW YORK Shares of Noven Pharmaceuticals Inc.fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.
Analyst David Windley lowered his rating to 'Underperform'...
Noven Pharma falls after analyst cuts rating NEW YORK - Shares of Noven Pharmaceuticals Inc.fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.
Analyst David Windley lowered his rating to 'Underperform'...
Noven Pharma falls after analyst cuts rating Shares of Noven Pharmaceuticals Inc.fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.
Analyst David Windley lowered his rating to 'Underperform' from 'Hold...
Noven Pharma falls after analyst cuts rating Analyst David Windley lowered his rating to 'Underperform' from 'Hold' due to declining growth in sales of the Vivelle-Dot estrogen patch and the Daytrana attention deficit hyperactivity disorder patch, which has been damaged by a...
Noven Pharma falls after analyst cuts rating NEW YORK (AP) -- Shares of Noven Pharmaceuticals Inc.fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.Analyst David Windley lowered his rating to ...
Analyst Actions: Jefferies Cuts Rating on Noven Pharma - Plunges 10% Jefferies also cut its price target to $9 per share from $11.The stock last traded at $9 on April 30.
The company makes patches that deliver drugs through the skin and Jefferies believes there is little potential in Noven's pipeline.
Johnson & Johnson Grows Up a Little Johnson & Johnson's (NYSE: JNJ) attention deficit hyperactivity disorder (ADHD) pill, Concerta, is growing up.On Friday, the Food and Drug Administration approved the drug for adults.
Concerta, a long-acting version of Novartis'...
